News Search Results
Jan 07, 2025, 09:00 ET Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
2025 /PRNewswire/ -- Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, and Duality Biotherapeutics ("DualityBio"), a clinical-stage biotech company focusing on
More news about: Duality Biotherapeutics
Jan 07, 2025, 09:00 ET TruLab Is Now TruTechnologies With a Bold Vision for Clinical Trials
timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations. Learn more at
More news about: TruTechnologies
Jan 07, 2025, 09:00 ET ZymoChem Achieves Certified B Corporation™ Status
contributor to U.S. landfill waste. The dual recognition as a PBC and a B Corp solidifies ZymoChem's reputation as a sustainability leader in the biotechnology industry – and it aims to inspire other companies in the sector to embed sustainability and social impact into their business models. To
More news about: ZymoChem
Jan 07, 2025, 08:42 ET InnoGI Technologies and Bac3Gel Forge Partnership to Revolutionize Gut Microbiome Research
LinkedIn. About Bac3GelBac3Gel is a biotechnology company that harnesses the power of the microbiome by replicating the complexity of native ecosystems and providing microbiota with the conditions
More news about: InnoGI Technologies
Jan 07, 2025, 08:00 ET Child's Cure Genetic Research collaborates with Matica Bio to Drive Innovation in Pediatric Rare Disease Therapies
COLLEGE STATION, Texas, Jan. 7, 2025 /PRNewswire/ -- Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector development
More news about: Matica Biotechnology, Inc.
Jan 07, 2025, 08:00 ET Trailhead Biosystems Welcomes Dr. Wolfgang Hofmann, MD to Its Board of Directors
Ohio, Jan. 7, 2025 /PRNewswire/ -- Trailhead Biosystems, a pioneering biotechnology company specializing in the development of iPSC-derived human cells for drug discovery and cell therapy, is pleased to announce the appointment
More news about: Trailhead Biosystems Inc
Jan 07, 2025, 08:00 ET Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
Verismo Therapeutics, a clinical-stage biotechnology company developing the novel KIR-CAR platform for solid tumors and blood cancers, today announced a strategic investment from the
More news about: Verismo Therapeutics
Jan 07, 2025, 07:45 ET QurAlis Invited to Present at 43rd Annual J.P. Morgan Healthcare Conference
QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral
More news about: QurAlis
Jan 07, 2025, 07:15 ET Avista Therapeutics Appoints Steven Altschuler, MD, as Chairman of the Board of Directors
Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced the appointment of Steven Altschuler,
More news about: Avista Therapeutics
Jan 07, 2025, 07:05 ET Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors
patients." Mr. Guggenhime has nearly three decades of experience in the biotechnology and healthcare industries. He currently serves as President and Chief Financial Officer of Vaxcyte, Inc., a NASDAQ-listed biotechnology company developing novel vaccines for bacterial infections, where he was instrumental
More news about: Sling Therapeutics, Inc.
Jan 07, 2025, 07:00 ET Esphera SynBio closes seed financing round to develop nanomedicine vaccines for cancer and infectious disease
Ontario and Ottawa, Ontario. About Esphera SynBio Inc. Esphera is a seed stage Canadian biotechnology company combining innovative technologies developed at McMaster University and the Ottawa Hospital Research Institute.
More news about: Esphera SynBio
Jan 07, 2025, 06:30 ET Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Jan 07, 2025, 02:00 ET Senseera Raises $7.1 Million Seed Round Led by Lightspeed Venture Partners
is built on decades of research led by Prof. Nir Friedman and validated in top-tier journals such as Nature Biotechnology. Supported by data from over 20,000 human samples, Senseera has established a robust foundation for accelerating drug development and precision
More news about: Senseera
Jan 06, 2025, 21:26 ET TCBP Issues 25% Stock Dividend
Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally
More news about: TC BioPharm
Jan 06, 2025, 19:00 ET Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening diseases, today announced the first patient dosed in the
More news about: Adcentrx Therapeutics
Jan 06, 2025, 19:00 ET WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases. Under the terms of the agreement,
More news about: WuXi Biologics
Jan 06, 2025, 17:31 ET Idiopathic Inflammatory Myositis Market Predicted to Show Positive Growth at a Tremendous CAGR of 21.1% by 2034 | DelveInsight
Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Viela Bio, Paean Biotechnology Inc., Alexion Pharmaceuticals, Janssen Biotech, CSL Behring, Pfizer, Roche, among others.
More news about: DelveInsight Business Research, LLP
Jan 06, 2025, 15:45 ET Amino Acid Fertilizer Market to Grow by USD 392.4 Million (2025-2029), Driven by Global Agricultural Initiatives and AI-Powered Market Evolution - Technavio
forms, are essential components of sustainable food systems, contributing to food security and crop yield enhancement. Agricultural innovation and biotechnology play a crucial role in the development of eco-friendly amino acid fertilizers, promoting water-efficient farming and reducing greenhouse gas emissions.
More news about: Technavio
Jan 06, 2025, 13:30 ET TCBP Trading Continues Unabated on Nasdaq Stock Exchange
Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository
More news about: TC BioPharm
Jan 06, 2025, 12:15 ET Dose Escalation Completed for Rise Therapeutics' R-3750 and R-2487 Clinical Trials
Md., Jan. 6, 2025 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its
More news about: Rise Therapeutics
Jan 06, 2025, 10:30 ET Companion Animal Diagnostics Market to Hit US$ 4.55 Billion by 2029 with 8.8% CAGR | MarketsandMarkets™
Germany), Swissavans AG (Switzerland), Skyla Corporation (Taiwan), Ring Biotechnology Co Ltd (China), and Alvedia (France). IDEXX (US): IDEXX is
More news about: MarketsandMarkets
Jan 06, 2025, 09:15 ET NanoImaging Services Acquires Proteos, Enhancing Integrated Protein Sciences and Structure-Based Discovery Capabilities
About NanoImaging ServicesNanoImaging Services, Inc. was launched in 2007 to provide imaging services to the pharmaceutical, biotechnology, and nanotechnology communities, and has since built a client-focused organization with a reputation for expertise, reliability, and collaboration.
More news about: NanoImaging Services
Jan 06, 2025, 09:00 ET Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market
licensing discussions. Exosomes embody an elegant evolution in biotechnology, and Exousia Pro is committed to spearheading their commercialization and therapeutic development." About us Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential
More news about: Marijuana Inc.
Jan 06, 2025, 09:00 ET NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from
More news about: NeuroSense
Jan 06, 2025, 09:00 ET Cahill Announces Election of Four New Partners and Two New Counsel
software, microchip technology, and medical devices, Andy focuses his practice mainly on complex patent litigation matters involving pharmaceuticals, biotechnology, and biologics/biosimilars. Partner Michael Dvorak focuses his practice on matters related to banking
More news about: Cahill Gordon & Reindel LLP